Published in Arthritis Res Ther on November 12, 2012
Advances in the regulation of osteoclasts and osteoclast functions. J Dent Res (2013) 1.16
Th17 and Th22 cells in psoriatic arthritis and psoriasis. Arthritis Res Ther (2013) 1.03
Advances in osteoclast biology reveal potential new drug targets and new roles for osteoclasts. J Bone Miner Res (2013) 0.99
TREM2 Protein Expression Changes Correlate with Alzheimer's Disease Neurodegenerative Pathologies in Post-Mortem Temporal Cortices. Brain Pathol (2014) 0.98
Osteoimmunology: Major and Costimulatory Pathway Expression Associated with Chronic Inflammatory Induced Bone Loss. J Immunol Res (2015) 0.89
Immunolocalization of MMP-2 and MMP-9 in human rheumatoid synovium. Int J Clin Exp Pathol (2014) 0.86
A potential role of myeloid DAP12-associating lectin (MDL)-1 in the regulation of inflammation in rheumatoid arthritis patients. PLoS One (2014) 0.81
Inactivation of DAP12 in PMN inhibits TREM1-mediated activation in rheumatoid arthritis. PLoS One (2015) 0.80
A Comprehensive Review of Immunoreceptor Regulation of Osteoclasts. Clin Rev Allergy Immunol (2016) 0.78
Mediators of inflammation and bone remodeling in rheumatic disease. Semin Cell Dev Biol (2015) 0.76
TREM2 in Neurodegenerative Diseases. Mol Neurodegener (2017) 0.75
Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods (2001) 414.27
The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum (1988) 111.05
Development of criteria for the classification and reporting of osteoarthritis. Classification of osteoarthritis of the knee. Diagnostic and Therapeutic Criteria Committee of the American Rheumatism Association. Arthritis Rheum (1986) 29.12
Induction and activation of the transcription factor NFATc1 (NFAT2) integrate RANKL signaling in terminal differentiation of osteoclasts. Dev Cell (2002) 9.10
Costimulatory signals mediated by the ITAM motif cooperate with RANKL for bone homeostasis. Nature (2004) 4.92
The molecular understanding of osteoclast differentiation. Bone (2006) 4.39
Impaired osteoclastic bone resorption leads to osteopetrosis in cathepsin-K-deficient mice. Proc Natl Acad Sci U S A (1998) 3.60
A DAP12-mediated pathway regulates expression of CC chemokine receptor 7 and maturation of human dendritic cells. J Exp Med (2001) 3.18
The immunomodulatory adapter proteins DAP12 and Fc receptor gamma-chain (FcRgamma) regulate development of functional osteoclasts through the Syk tyrosine kinase. Proc Natl Acad Sci U S A (2004) 3.15
Cutting edge: inhibition of TLR and FcR responses in macrophages by triggering receptor expressed on myeloid cells (TREM)-2 and DAP12. J Immunol (2006) 2.73
Identification of cell types responsible for bone resorption in rheumatoid arthritis and juvenile rheumatoid arthritis. Am J Pathol (1998) 2.68
Synovial membrane inflammation and cytokine production in patients with early osteoarthritis. J Rheumatol (1997) 2.43
Reduction of synovial inflammation after anti-CD4 monoclonal antibody treatment in early rheumatoid arthritis. Arthritis Rheum (1995) 2.25
Osteoclast-osteoblast communication. Arch Biochem Biophys (2008) 2.22
Role of ITAM-containing adapter proteins and their receptors in the immune system and bone. Immunol Rev (2005) 2.08
Rheumatic diseases: the effects of inflammation on bone. Immunol Rev (2005) 2.07
A novel member of the leukocyte receptor complex regulates osteoclast differentiation. J Exp Med (2002) 2.04
DAP12/TREM2 deficiency results in impaired osteoclast differentiation and osteoporotic features. J Exp Med (2003) 2.04
Cathepsin K knockout mice develop osteopetrosis due to a deficit in matrix degradation but not demineralization. J Bone Miner Res (1999) 2.02
Activated human T cells directly induce osteoclastogenesis from human monocytes: possible role of T cells in bone destruction in rheumatoid arthritis patients. Arthritis Rheum (2001) 1.85
Osteoprotegerin expression in synovial tissue from patients with rheumatoid arthritis, spondyloarthropathies and osteoarthritis and normal controls. Rheumatology (Oxford) (2003) 1.83
Cloning and characterization of a novel mouse myeloid DAP12-associated receptor family. Eur J Immunol (2001) 1.78
Variability in cytokine and cell adhesion molecule staining in arthroscopic synovial biopsies: quantification using color video image analysis. J Rheumatol (1997) 1.77
Nuclear factor of activated T cells c1 induces osteoclast-associated receptor gene expression during tumor necrosis factor-related activation-induced cytokine-mediated osteoclastogenesis. J Biol Chem (2005) 1.62
TREM2, a DAP12-associated receptor, regulates osteoclast differentiation and function. J Bone Miner Res (2005) 1.48
Pathogenesis of bone erosions in rheumatoid arthritis. Curr Opin Rheumatol (2000) 1.46
Osteoimmunology: crosstalk between the immune and bone systems. J Clin Immunol (2009) 1.39
Osteoprotegerin and receptor activator of nuclear factor kappaB ligand (RANKL) regulate osteoclast formation by cells in the human rheumatoid arthritic joint. Rheumatology (Oxford) (2001) 1.35
RANKL protein is expressed at the pannus-bone interface at sites of articular bone erosion in rheumatoid arthritis. Rheumatology (Oxford) (2006) 1.34
Immunohistological analysis of synovial tissue for differential diagnosis in early arthritis. Rheumatology (Oxford) (1999) 1.30
NFATc1 regulation of the human beta3 integrin promoter in osteoclast differentiation. Gene (2006) 1.28
Osteoprotegerin (OPG) is localized to the Weibel-Palade bodies of human vascular endothelial cells and is physically associated with von Willebrand factor. J Cell Physiol (2005) 1.27
Receptor activator NF-kappaB ligand (RANKL) expression in synovial tissue from patients with rheumatoid arthritis, spondyloarthropathy, osteoarthritis, and from normal patients: semiquantitative and quantitative analysis. Ann Rheum Dis (2002) 1.21
Osteoclast-like cells in murine collagen induced arthritis. J Rheumatol (1998) 1.11
Fcgamma receptors directly mediate cartilage, but not bone, destruction in murine antigen-induced arthritis: uncoupling of cartilage damage from bone erosion and joint inflammation. Arthritis Rheum (2006) 1.10
Involvement of FcRgamma in signal transduction of osteoclast-associated receptor (OSCAR). Int Immunol (2004) 1.10
Regulation of TREM expression in hepatic macrophages and endothelial cells during acute endotoxemia. Exp Mol Pathol (2007) 1.06
Microarchitecture and protective mechanisms in synovial tissue from clinically and arthroscopically normal knee joints. Ann Rheum Dis (2003) 1.06
The induction of a catabolic phenotype in human primary osteoblasts and osteocytes by polyethylene particles. Biomaterials (2009) 1.01
OSCAR is an FcRgamma-associated receptor that is expressed by myeloid cells and is involved in antigen presentation and activation of human dendritic cells. Blood (2004) 1.00
The role of osteoclast-associated receptor in osteoimmunology. J Immunol (2011) 0.97
Enhanced NFATc1 nuclear occupancy causes T cell activation independent of CD28 costimulation. J Immunol (2007) 0.96
Molecular mechanisms underlying osteoclast formation and activation. Exp Gerontol (2003) 0.96
Association of the OSCAR promoter polymorphism with BMD in postmenopausal women. J Bone Miner Res (2005) 0.95
Role of cathepsin K in the turnover of the dermal extracellular matrix during scar formation. J Invest Dermatol (2006) 0.94
The role played by cell-substrate interactions in the pathogenesis of osteoclast-mediated peri-implant osteolysis. Arthritis Res Ther (2006) 0.92
PU.1 and NFATc1 mediate osteoclastic induction of the mouse beta3 integrin promoter. J Cell Physiol (2008) 0.91
Costimulatory pathways in rheumatoid synovitis and T-cell senescence. Ann N Y Acad Sci (2005) 0.90
Induction of osteoclast-associated receptor, a key osteoclast costimulation molecule, in rheumatoid arthritis. Arthritis Rheum (2008) 0.90
Expression and regulation of cathepsin K in skin fibroblasts. Exp Dermatol (2009) 0.86
Ligation of the FcR gamma chain-associated human osteoclast-associated receptor enhances the proinflammatory responses of human monocytes and neutrophils. J Immunol (2006) 0.86
TWEAK and Fn14 expression in the pathogenesis of joint inflammation and bone erosion in rheumatoid arthritis. Arthritis Res Ther (2011) 0.86
The osteoclast-associated receptor (OSCAR) is a novel receptor regulated by oxidized low-density lipoprotein in human endothelial cells. Endocrinology (2011) 0.84
New insights into the regulation of cathepsin K gene expression by osteoprotegerin ligand. Biochem Biophys Res Commun (2001) 0.83
Fc receptor gamma-chain activation via hOSCAR induces survival and maturation of dendritic cells and modulates Toll-like receptor responses. Blood (2005) 0.82
Regulation of ITAM adaptor molecules and their receptors by inhibition of calcineurin-NFAT signalling during late stage osteoclast differentiation. Biochem Biophys Res Commun (2012) 0.81
Bone matrix regulates osteoclast differentiation and annexin A8 gene expression. J Cell Physiol (2011) 0.78
Polyethylene particles stimulate expression of ITAM-related molecules in peri-implant tissues and when stimulating osteoclastogenesis in vitro. Acta Biomater (2012) 0.78
Changes in serum levels of soluble osteoclast-associated receptor in human rheumatoid arthritis. Chin Med J (Engl) (2011) 0.77
Molecular and cellular characterisation of highly purified stromal stem cells derived from human bone marrow. J Cell Sci (2003) 4.10
Receptor activator of nuclear factor-kappaB ligand expression by human myeloma cells mediates osteoclast formation in vitro and correlates with bone destruction in vivo. Cancer Res (2003) 2.73
Concise review: mesenchymal stromal cells: potential for cardiovascular repair. Stem Cells (2008) 2.39
Rheumatic diseases: the effects of inflammation on bone. Immunol Rev (2005) 2.07
A novel monoclonal antibody (STRO-3) identifies an isoform of tissue nonspecific alkaline phosphatase expressed by multipotent bone marrow stromal stem cells. Stem Cells Dev (2007) 1.96
Macrophage colony-stimulating factor receptor c-fms is a novel target of imatinib. Blood (2005) 1.80
Metabolism of vitamin D3 in human osteoblasts: evidence for autocrine and paracrine activities of 1 alpha,25-dihydroxyvitamin D3. Bone (2007) 1.52
Modulation of RANKL and osteoprotegerin expression in synovial tissue from patients with rheumatoid arthritis in response to disease-modifying antirheumatic drug treatment and correlation with radiologic outcome. Arthritis Rheum (2008) 1.51
TWIST family of basic helix-loop-helix transcription factors mediate human mesenchymal stem cell growth and commitment. Stem Cells (2009) 1.47
RANKL expression is related to the differentiation state of human osteoblasts. J Bone Miner Res (2003) 1.46
Pro-inflammatory cytokines TNF-related weak inducer of apoptosis (TWEAK) and TNFalpha induce the mitogen-activated protein kinase (MAPK)-dependent expression of sclerostin in human osteoblasts. J Bone Miner Res (2009) 1.36
RANK Expression as a cell surface marker of human osteoclast precursors in peripheral blood, bone marrow, and giant cell tumors of bone. J Bone Miner Res (2006) 1.33
Snail regulates cell-matrix adhesion by regulation of the expression of integrins and basement membrane proteins. J Biol Chem (2008) 1.32
Long-term imatinib therapy promotes bone formation in CML patients. Blood (2007) 1.30
Dysregulation of bone remodeling by imatinib mesylate. Blood (2009) 1.26
The Jak-STAT pathway in rheumatoid arthritis. J Rheumatol (2005) 1.26
Mechanisms and control of pathologic bone loss in periodontitis. Periodontol 2000 (2010) 1.26
Implanted adult human dental pulp stem cells induce endogenous axon guidance. Stem Cells (2009) 1.24
Pre-existing periodontitis exacerbates experimental arthritis in a mouse model. J Clin Periodontol (2011) 1.22
Genomic profiling of mesenchymal stem cells. Stem Cell Rev (2009) 1.20
Serum macrophage inhibitory cytokine 1 in rheumatoid arthritis: a potential marker of erosive joint destruction. Arthritis Rheum (2007) 1.15
Receptor activator NF kappaB ligand (RANKL) and osteoprotegerin (OPG) protein expression in periodontitis. J Periodontal Res (2003) 1.11
Effects of Osteochondrin S and select connective tissue ribonucleinate components on human osteoclasts in vitro. J Pharm Pharmacol (2013) 1.08
The proliferation and phenotypic expression of human osteoblasts on tantalum metal. Biomaterials (2004) 1.07
The nitrogen-containing bisphosphonate, zoledronic acid, increases mineralisation of human bone-derived cells in vitro. Bone (2004) 1.06
Cloning and characterization of osteoclast precursors from the RAW264.7 cell line. In Vitro Cell Dev Biol Anim (2006) 1.05
Effect of Porphyromonas gingivalis-induced inflammation on the development of rheumatoid arthritis. J Clin Periodontol (2010) 1.04
The tyrosine kinase inhibitor dasatinib dysregulates bone remodeling through inhibition of osteoclasts in vivo. J Bone Miner Res (2010) 1.02
The induction of a catabolic phenotype in human primary osteoblasts and osteocytes by polyethylene particles. Biomaterials (2009) 1.01
Apomab, a fully human agonistic antibody to DR5, exhibits potent antitumor activity against primary and metastatic breast cancer. Mol Cancer Ther (2009) 1.00
Targeted disruption of the CXCL12/CXCR4 axis inhibits osteolysis in a murine model of myeloma-associated bone loss. J Bone Miner Res (2009) 1.00
NVP-BEZ235, a dual pan class I PI3 kinase and mTOR inhibitor, promotes osteogenic differentiation in human mesenchymal stromal cells. J Bone Miner Res (2010) 1.00
CD36/fatty acid translocase in rats: distribution, isolation from hepatocytes, and comparison with the scavenger receptor SR-B1. Lab Invest (2003) 0.98
Brief report: the differential roles of mTORC1 and mTORC2 in mesenchymal stem cell differentiation. Stem Cells (2015) 0.97
Reduced chemokine and matrix metalloproteinase expression in patients with rheumatoid arthritis achieving remission. J Rheumatol (2003) 0.97
Hypoxia-inducible factor-2 is a novel regulator of aberrant CXCL12 expression in multiple myeloma plasma cells. Haematologica (2009) 0.97
Myeloma plasma cells alter the bone marrow microenvironment by stimulating the proliferation of mesenchymal stromal cells. Haematologica (2013) 0.97
The nitrogen-containing bisphosphonate, zoledronic acid, influences RANKL expression in human osteoblast-like cells by activating TNF-alpha converting enzyme (TACE). J Bone Miner Res (2004) 0.96
Elevated expression of caspase-3 inhibitors, survivin and xIAP correlates with low levels of apoptosis in active rheumatoid synovium. Arthritis Res Ther (2009) 0.96
Therapeutic effects of human STRO-3-selected mesenchymal precursor cells and their soluble factors in experimental myocardial ischemia. J Cell Mol Med (2011) 0.96
Mechanisms of bone loss in rheumatoid arthritis. Mod Rheumatol (2005) 0.95
Suppression of PDGF-induced PI3 kinase activity by imatinib promotes adipogenesis and adiponectin secretion. J Mol Endocrinol (2012) 0.95
Heat shock protein-90 beta is expressed at the surface of multipotential mesenchymal precursor cells: generation of a novel monoclonal antibody, STRO-4, with specificity for mesenchymal precursor cells from human and ovine tissues. Stem Cells Dev (2009) 0.95
Epigenetic regulation of inflammation: progressing from broad acting histone deacetylase (HDAC) inhibitors to targeting specific HDACs. Inflammopharmacology (2013) 0.95
A method to isolate and purify human bone marrow stromal stem cells. Methods Mol Biol (2008) 0.95
South Australian Scleroderma Register: autoantibodies as predictive biomarkers of phenotype and outcome. Int J Rheum Dis (2011) 0.94
Vitamin D(2) supplementation induces the development of aortic stenosis in rabbits: interactions with endothelial function and thioredoxin-interacting protein. Eur J Pharmacol (2008) 0.94
The correlation of RANK, RANKL and TNFalpha expression with bone loss volume and polyethylene wear debris around hip implants. Biomaterials (2006) 0.93
Impact of timing and dose of mesenchymal stromal cell therapy in a preclinical model of acute myocardial infarction. J Card Fail (2013) 0.93
Inhibition of c-fms by imatinib: expanding the spectrum of treatment. Cell Cycle (2005) 0.93
Apo2L/TRAIL inhibits tumor growth and bone destruction in a murine model of multiple myeloma. Clin Cancer Res (2009) 0.93
Inflammatory cells and bone loss in rheumatoid arthritis. Arthritis Res Ther (2007) 0.92
The role played by cell-substrate interactions in the pathogenesis of osteoclast-mediated peri-implant osteolysis. Arthritis Res Ther (2006) 0.92
Only one independent genetic association with rheumatoid arthritis within the KIAA1109-TENR-IL2-IL21 locus in Caucasian sample sets: confirmation of association of rs6822844 with rheumatoid arthritis at a genome-wide level of significance. Arthritis Res Ther (2010) 0.92
Optimization of the cardiovascular therapeutic properties of mesenchymal stromal/stem cells-taking the next step. Stem Cell Rev (2013) 0.91
Imatinib as a potential antiresorptive therapy for bone disease. Blood (2006) 0.91
Anticancer efficacy of Apo2L/TRAIL is retained in the presence of high and biologically active concentrations of osteoprotegerin in vivo. J Bone Miner Res (2011) 0.90
Identification of a common gene expression signature associated with immature clonal mesenchymal cell populations derived from bone marrow and dental tissues. Stem Cells Dev (2010) 0.89
Human trabecular bone-derived osteoblasts support human osteoclast formation in vitro in a defined, serum-free medium. J Cell Physiol (2005) 0.89
The role of the chemokine CXCL12 in osteoclastogenesis. Trends Endocrinol Metab (2007) 0.89
Synovial tissue analysis in clinical trials. J Rheumatol (2005) 0.88
Assessment of myocardial fibrosis by endoventricular electromechanical mapping in experimental nonischemic cardiomyopathy. Int J Cardiovasc Imaging (2010) 0.88
Potential roles of growth factor PDGF-BB in the bony repair of injured growth plate. Bone (2009) 0.88
Intramyocardial navigation and mapping for stem cell delivery. J Cardiovasc Transl Res (2009) 0.87
Isolation of a human homolog of osteoclast inhibitory lectin that inhibits the formation and function of osteoclasts. J Bone Miner Res (2004) 0.87
Reparative effects of allogeneic mesenchymal precursor cells delivered transendocardially in experimental nonischemic cardiomyopathy. JACC Cardiovasc Interv (2010) 0.87
"My foot hurts": a flare of rheumatoid arthritis? Med J Aust (2009) 0.86
Tumor angiogenesis is associated with plasma levels of stromal-derived factor-1alpha in patients with multiple myeloma. Clin Cancer Res (2006) 0.86
TWEAK and Fn14 expression in the pathogenesis of joint inflammation and bone erosion in rheumatoid arthritis. Arthritis Res Ther (2011) 0.86
An injectable hydrogel incorporating mesenchymal precursor cells and pentosan polysulphate for intervertebral disc regeneration. Biomaterials (2013) 0.86
Bone remodelling in inflammatory arthritis. Ann Rheum Dis (2012) 0.86
Application of autologous bone marrow derived mesenchymal stem cells to an ovine model of growth plate cartilage injury. Open Orthop J (2010) 0.85
Microarray expression analysis of genes and pathways involved in growth plate cartilage injury responses and bony repair. Bone (2012) 0.85
Histopathological and ultrastructural features of dermal telangiectasias in systemic sclerosis. Pathology (2005) 0.84
Periprosthetic osteolysis after total hip replacement: molecular pathology and clinical management. Inflammopharmacology (2013) 0.83
A novel promoter regulates calcitonin receptor gene expression in human osteoclasts. Biochim Biophys Acta (2007) 0.83
Effects of low-dose prednisolone on hepatic and peripheral insulin sensitivity, insulin secretion, and abdominal adiposity in patients with inflammatory rheumatologic disease. Diabetes Care (2013) 0.83
OCT-1 function varies with cell lineage but is not influenced by BCR-ABL. Haematologica (2010) 0.83
Methods for the purification and characterization of human adipose-derived stem cells. Methods Mol Biol (2011) 0.83
Plasma adiponectin levels are markedly elevated in imatinib-treated chronic myeloid leukemia (CML) patients: a mechanism for improved insulin sensitivity in type 2 diabetic CML patients? J Clin Endocrinol Metab (2010) 0.82
The expression of RANKL and OPG in the various grades of osteoarthritic cartilage. Rheumatol Int (2011) 0.82
Esophageal adenocarcinoma and hypertrophic osteoarthropathy with improvement following resection of esophageal cancer. J Clin Rheumatol (2011) 0.82
Protein kinase activity of phosphoinositide 3-kinase regulates cytokine-dependent cell survival. PLoS Biol (2013) 0.82
EphB4 enhances the process of endochondral ossification and inhibits remodeling during bone fracture repair. J Bone Miner Res (2013) 0.82
Development of a novel recombinant biotherapeutic with applications in targeted therapy of human arthritis. Arthritis Rheum (2011) 0.82
An ovine model of toxic, nonischemic cardiomyopathy--assessment by cardiac magnetic resonance imaging. J Card Fail (2008) 0.82
Prospective histomorphometric and DXA evaluation of bone remodeling in imatinib-treated CML patients: evidence for site-specific skeletal effects. J Clin Endocrinol Metab (2012) 0.82
The biologic response to particles from a lumbar disc prosthesis. Spine (Phila Pa 1976) (2002) 0.81
Variability of RANKL and osteoprotegerin staining in synovial tissue from patients with active rheumatoid arthritis: quantification using color video image analysis. J Rheumatol (2003) 0.81
Histone deacetylase inhibitors as suppressors of bone destruction in inflammatory diseases. J Pharm Pharmacol (2011) 0.81
Circulating N-cadherin levels are a negative prognostic indicator in patients with multiple myeloma. Br J Haematol (2013) 0.81